Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Serono Disappointed With Phase II Matuzumab Data (Japan)

This article was originally published in PharmAsia News

Executive Summary

Merck Serono, the biopharmaceutical unit of Germany's Merck KGaA, says that data from a mid-stage trial of its investigational cancer compound matuzumab is disappointing. The drug, a humanized monoclonal antibody, is being co-developed with Japan's Takeda Pharmaceutical Co. Merck Serono reports that a Phase II trial investigating matuzumab in combination with irinotecan in patients with metastatic colorectal cancer who had already failed on multiple prior treatments "has not met its predefined endpoint of activity." Merck Serono adds that Takeda Pharmaceutical shares its view that the study results do not meet expectations. However, they are not giving up on the compound and will continue to study matuzumab in other tumors including non-small cell lung cancer. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel